US Kidney Research Corporation (USKRC) Granted US Patent
USPTO grants patent for new blood purifying technology
Roseville, CA (PRUnderground) October 7th, 2020
US Kidney Research Corporation (USKRC) U.S. Application No. 15/732,169 was approved and a patent was granted by the US Patent Office on October 2, 2020. The patent was granted for their Dialysate Free Artificial Kidney Device, the company’s waterless renal replacement therapy technology.
Founder/CEO Roland Ludlow said “We are very pleased to finally have our US Patent granted. It was a long process. Due to the amount of patents processed by the USPTO, it was a 2 ½ year wait before the initial patent examination took place. Fortunately, with the excellent help from our patent attorneys at Morrison Forester, the final examination and approval was completed in less than 6 months from the initial examination. The entire process took nearly 3 years from start to finish”.
US Kidney Research Corporation has also filed numerous foreign PCT patent applications through the European Patent Office (EPO). These included all the primary EPO member countries (Europe), plus China, Japan, S. Korea, India, Singapore, Australia, Mexico, and Canada.
About US Kidney Research Corporation
US Kidney Research Corporation (USKRC) is a Delaware C-Corp founded in June, 2015. USKRC is a leader in the field of artificial kidney research and involved in R&D of the world’s first waterless renal replacement technology.
Contrary to dialysis, their new technology does not require purified water, dialysate concentrate solutions, or a dialyzer, providing significant advantages for both the patient and provider. Their novel waterless blood purification technology is leading to the creation of a truly artificial kidney to replace dialysis and native kidney transplantation. Additionally, the same technology is being used to develop a wearable artificial kidney, a standalone device, and ultimately an implantable artificial kidney.
USKRC is currently finishing their wearable backpack prototype. The company says that with adequate funding their backpack prototype for blood purification can be completed and ready for clinical trials within 2 years.
The company’s future plans include advancing their technology, miniaturizing their prototype for use in an implantable artificial kidney, and creating a standalone device for use in home and clinics. The company is also advancing their new non-clotting filtering technology and studying the role of middle molecules (uremic toxins) including a method to detect, identify, and isolate them.
USKRC is working with Dr. Ira Kurtz, their Science/Medical Advisor/Board Member, whom also is the Chief of Nephrology at the University of California Los Angeles (UCLA) and with researchers from the Department of Chemical Engineering at the University of Arkansas, headed by Dr. Jamie Hestekin.